139 results about "Human cancer" patented technology

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention belongs to the technical field of medicinal chemistry, and discloses a paeonol mannich base-rhein conjugate as well as a preparation method and application thereof. The conjugate is a compound as shown in a general formula (I) or (II) or a pharmaceutically acceptable salt thereof. Compared with the clinically common antitumor drugs fluorouracil and paeonol, the conjugate provided by the invention has obviously higher in-vitro anti-human hepatoma carcinoma cell (HepG2) and human lung cancer cell (A549) proliferative activity, and the in-vitro anti-human cervical carcinoma cell (Hela), human colon cancer cell (HT29) and human osteosarcoma cell (U2OS) proliferative activity of most compounds is obviously superior to that of fluorouracil and paeonol; and the conjugate has good water solubility, is expected to be applied to treatment of various cancers such as cervical cancer, colon cancer, osteosarcoma, lung cancer or liver cancer, and has a wide clinical application prospect. # imgabs0 #

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses a miRNA-SNPs fluorescent sensor based on PfAgo protein programmable nuclease activity and a sensing method and application of the miRNA-SNPs fluorescent sensor. The fluorescent sensor comprises a chain A, a chain B, SplintR ligase, FQ and PfAgo nuclease. The chain A and the chain B generate a chain AB complementary to the miRNA to be detected through a base complementary pairing principle and the action of SplintR ligase; the AB chain excites PfAgo nuclease to perform targeted cleavage on an FQ single chain, so that a fluorophore FAM on the FQ single chain is separated from a quenching group BHQ1. According to the sensor and the sensing method thereof disclosed by the invention, zero background and accurate quantification of miRNA with mutated single basic group can be realized. The invention provides a simple, rapid and ultra-sensitive miRNA-SNPs accurate quantification strategy, and provides a powerful and universal detection platform for prognosis of human cancers related to miRNA related single nucleotide polymorphism.

Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xα in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.

The invention relates to methods for treating a cancer patient comprising administering a Zn(II) agent or a Zn(II) agent / immune-oncology agent combination to provide a therapeutic benefit to the cancer patient. The methods are useful in treating a broad spectrum of human cancers, including solid tumors and blood-based cancerous cells. In particular embodiments, the treatment methods are directed to cancer types characterized by genetic instability mutations.

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The invention discloses an application of a compound targeting SND1, and is characterized in that the compound targeting SND1 is applied to preparation of an SND1 inhibitor, and the structural formula of the compound targeting SND1 is as follows: # imgabs0 #. According to the present invention, the inhibitor screening is performed on the nuclease-containing structural domain 1 (SND1) protein of the staphylococcus capable of mediating the occurrence and the development of the tumors, the fact that the compound represented by the structural formula I can target the SND1, and has good inhibition activity on a variety of different types of human cancer cells is found for the first time, and the optional scheme is provided for the broad-spectrum anti-cancer drug. The compound applied in the invention can be artificially synthesized, and the production cost is low.

The present disclosure relates to systems, software and methods for detecting residual diseases, such as residual neoplastic diseases, in a subject, such as a human cancer patient.

The present invention relates to novel anti-p95HER2 antibodies (as monoclonal antibodies or in other forms, such as bispecific or multispecific forms) and compositions comprising such antibodies or cells activated by such antibodies for use in the treatment of conditions associated with p95HER2, such as human cancer therapy.

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

The present invention provides a combination comprising a) an antigen binding domain specific for CD90, and b) an antigen binding domain specific for CD326, for use in treatment of human cancer comprising cancerous cells that co-express CD90 and CD326. In one embodiment of the invention the combination comprises a) an immune cell comprising a CAR comprising an antigen binding domain specific for a tag of a first and a second polypeptide, b) said tagged first polypeptide that has an antigen binding domain specific for CD90, and c) said tagged second polypeptide that has an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical. In a further embodiment the concentrations used for said first and that second polypeptide are below the activation threshold of said CAR, respectively, but the sum of both concentrations is above the activation threshold of said CAR.

The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers. The NDIs are a compound of Formula I:

The present invention relates to an in vitro method for preparing an immunoreactive agent against human cancer cells infected with an HPV16-associated virus, said method comprising expressing at least part of a nucleic acid sequence encoding an immunoreactive agent obtained from an immune cell stimulated by a complex comprising a human leukocyte antigen (HLA) and a stimulating peptide (stimulating complex), wherein the stimulating peptide (i) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2, and the HLA is from an HLA supertype HLA-A01; (ii) consists of an amino acid sequence of SEQ ID NO: 11, and the HLA is from an HLA supertype HLA-A02; (iii) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 37, and the HLA is from an HLA supertype HLA-A03 / A11; (iv) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 60 and SEQ ID NO: 61, and the HLA is from an HLA supertype HLA-A24; (v) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61, SEQ ID NO: 76 and SEQ ID NO: 77, and the HLA is from an HLA supertype HLA-B07; or (vi) consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and SEQ ID NO: 85 to SEQ ID NO: 92, and the HLA is from an HLA supertype HLA-B15; and wherein HPV16-derived peptides consisting of the same amino acid sequence as the stimulating peptides have been demonstrated to be presented by human HPV16-positive cancer cells, and methods and uses related thereto.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The present invention relates to a monoclonal antibody against liver stem cells and a use thereof and, more specifically, to a monoclonal antibody and a use thereof for cell detection and cancer diagnosis, wherein the monoclonal antibody has a predetermined complementarity determination region and specifically binds to IP3R3 on the surface of naive human pluripotent stem cells, primed human pluripotent stem cells, liver stem cells, and human cancer cells.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including humans.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and particularly relates to a synthesis method of a novel polycyclic aromatic hydrocarbon derivate 2, 6-di-tert-butyl pyrene and indolizine phenothiazine compound and application of the compound in the aspect of anti-cancer drugs. The synthesis process is simple and convenient, conditions are mild, and the yield is ideal. Pharmacodynamic evaluation shows that the compound shows strong inhibitory activity on various human cancer cell lines, and the IC50 values are respectively cervical cancer Hela cells (0.17 mu M), lung cancer A549 cells (0.3 mu M), prostatic cancer PC-3 cells (0.42 mu M) and liver cancer HepG2 cells (10.79 mu M), which are respectively reduced by 109 times, 173 times, 35 times and 1.8 times compared with positive control drug cis-platinum. In addition to efficiently inhibiting cancer cells, the compound has low toxicity to normal cells, meets the basic requirements of excellent anti-cancer drugs, and shows important application value and potential in the field of research and development of novel anti-cancer drugs.

This disclosure provides a method for treating cancer in human subjects, comprising the administration of a recombinant polypeptide containing a cancer-specific CD8+ T cell epitope. The peptide, recognized by a major histocompatibility complex (MHC) molecule, can activate a T cell immune response to target cancer cells in the subject. This disclosure further provides a cancer-specific CD8+ T cell epitope constrained to an MHC molecule expressed by a specific HLA allele in the subject. This disclosure further provides a composition encoding a recombinant polypeptide capable of inducing an augmented memory CD8+ T cell response.

The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

The invention relates to a preparation method and application of a flavonoid diglycoside compound which is separated from a dry whole plant of daphne tenuifolia plant and has antineoplastic activity. The preparation method comprises the following steps: taking a dry whole plant of a daphne plant daphne gemma E.Pritz. Ex Diels as a raw material, and preparing a raw material from the dry whole plant, namely the daphne gemma E.Pritz. Ex Diels, of the daphne gemma E.Pritz. Ex Diels, of the daphne gemma E.Pritz. Ex Diels; the preparation method comprises the following steps: extracting an extract, extracting and concentrating, and then carrying out various separation methods such as silica gel column chromatography, reversed-phase ODS column chromatography and Sephadex LH-20 to obtain the flavonoid diglycoside compound: # imgabs0 #. The cytotoxic effects of the compounds I-III on three human cancer cell strains of lung cancer A549, breast cancer MDA-MB-231 and colon cancer SW480 are evaluated by adopting an MTS method; the compounds have strong anti-lung cancer and anti-breast cancer activity, and have potential anti-tumor drug research and development and application values.

This document relates to materials and methods involved in treating cancer. For example, materials and methods for using one or more oncolytic viruses (e.g., one or more oncolytic viruses) to treat cancer in a mammal (e.g., a human) identified as having a cancer likely to respond to oncolytic virotherapy are provided.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.